Skip to main content
SpringerLink
Log in

New Immunomodulatory Drugs in Myeloma

  • Published:
Current Hematologic Malignancy Reports Aims and scope Submit manuscript

Abstract

Multiple myeloma (MM) is an incurable malignancy of plasma cells. The introduction of thalidomide was a milestone in the treatment of MM. Thalidomide analogues termed immunomodulatory drugs (IMiDs) have been developed that are more effective and have less toxicity than thalidomide. The role of lenalidomide in relapsed MM has been well defined. This review discusses the data regarding the upfront use of lenalidomide with dexamethasone or in multidrug combinations, as well as its potential role as maintenance therapy. It also reviews our experience with pomalidomide, a new IMid with remarkable activity in relapsed, refractory MM.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

Papers of particular interests, published recently, have been highlighted as:• Of importance

  1. • Jemal A, Siegel R, Xu J, Ward E. Cancer statistics. CA Cancer J Clin. 2010;60:277–300. These are updated statistics regarding cancer incidence.

    Article  PubMed  Google Scholar 

  2. Singhal S, Mehta J, Desikan R, et al. Antitumor activity of thalidomide in refractory multiple myeloma [see comments]. N Engl J Med. 1999;341:1565–71.

    Article  PubMed  CAS  Google Scholar 

  3. • Kumar SK, Rajkumar SV, Dispenzieri A, et al. Improved survival in multiple myeloma and the impact of novel therapies. Blood. 2008;111:2516–20. This study shows survival in myeloma by decade and suggests that novel therapies are having a positive impact on overall survival in myeloma.

    Article  PubMed  CAS  Google Scholar 

  4. von Lilienfeld-Toal M, Hahn-Ast C, Furkert K, et al. A systematic review of phase II trials of thalidomide/dexamethasone combination therapy in patients with relapsed or refractory multiple myeloma. Eur J Haematol. 2008;81(4):247–52.

    Article  Google Scholar 

  5. Dimopoulos M, Spencer A, Attal M, et al. Lenalidomide plus dexamethasone for relapsed or refractory multiple myeloma. N Engl J Med. 2007;357:2123–32.

    Article  PubMed  CAS  Google Scholar 

  6. Weber DM, Chen C, Niesvizky R, et al. Lenalidomide plus dexamethasone for relapsed multiple myeloma in North America. N Engl J Med. 2007;357:2133–42.

    Article  PubMed  CAS  Google Scholar 

  7. Richardson PG, Barlogie B, Berenson J, et al. A phase 2 study of bortezomib in relapsed, refractory myeloma. N Engl J Med. 2003;348:2609–17.

    Article  PubMed  CAS  Google Scholar 

  8. Davies FE, Wu P, Jenner M, Srikanth M, Saso R, Morgan GJ. The combination of cyclophosphamide, Velcade and dexamethasone induces high response rates with comparable toxicity to Velcade alone and Velcade plus dexamethasone. Haematologica. 2007;92:1149–50.

    Article  PubMed  CAS  Google Scholar 

  9. Kropff M, Bisping G, Schuck E, et al. Bortezomib in combination with intermediate-dose dexamethasone and continuous low-dose oral cyclophosphamide for relapsed multiple myeloma. Br J Haematol. 2007;138:330–7.

    Article  PubMed  CAS  Google Scholar 

  10. Orlowski RZ, Nagler A, Sonneveld P, et al. Randomized phase III study of pegylated liposomal doxorubicin plus bortezomib compared with bortezomib alone in relapsed or refractory multiple myeloma: combination therapy improves time to progression. J Clin Oncol. 2007;25:3892–901.

    Article  PubMed  CAS  Google Scholar 

  11. Palumbo A, Ambrosini MT, Benevolo G, et al. Bortezomib, melphalan, prednisone, and thalidomide for relapsed multiple myeloma. Blood. 2007;109:2767–72.

    PubMed  CAS  Google Scholar 

  12. Reece DE, Rodriguez GP, Chen C, et al. Phase I–II trial of bortezomib plus oral cyclophosphamide and prednisone in relapsed and refractory multiple myeloma. J Clin Oncol. 2008;26:4777–83.

    Article  PubMed  CAS  Google Scholar 

  13. D’Amato RJ, Loughnan MS, Flynn E, Folkman J. Thalidomide is an inhibitor of angiogenesis. Proc Natl Acad Sci USA. 1994;91:4082–5.

    Article  PubMed  Google Scholar 

  14. Keifer JA, Guttridge DC, Ashburner BP, Baldwin Jr AS. Inhibition of NF-kappa B activity by thalidomide through suppression of IkappaB kinase activity. J Biol Chem. 2001;276:22382–7.

    Article  PubMed  CAS  Google Scholar 

  15. Mitsiades N, Mitsiades CS, Poulaki V, et al. Apoptotic signaling induced by immunomodulatory thalidomide analogs in human multiple myeloma cells: therapeutic implications. Blood. 2002;99:4525–30.

    Article  PubMed  CAS  Google Scholar 

  16. • Escoubet-Lozach L, Lin IL, Jensen-Pergakes K, et al. Pomalidomide and lenalidomide induce p21 WAF-1 expression in both lymphoma and multiple myeloma through a LSD1-mediated epigenetic mechanism. Cancer Res. 2009;69:7347–56. This shows the effects of IMiDs on p53.

    Article  PubMed  CAS  Google Scholar 

  17. Davies FE, Raje N, Hideshima T, et al. Thalidomide and immunomodulatory derivatives augment natural killer cell cytotoxicity in multiple myeloma. Blood. 2001;98:210–6.

    Article  PubMed  CAS  Google Scholar 

  18. Reddy N, Hernandez-Ilizaliturri FJ, Deeb G, et al. Immunomodulatory drugs stimulate natural killer-cell function, alter cytokine production by dendritic cells, and inhibit angiogenesis enhancing the anti-tumour activity of rituximab. Br J Haematol. 2008;140:36–45.

    PubMed  CAS  Google Scholar 

  19. Corral LG, Haslett PA, Muller GW, et al. Differential cytokine modulation and T cell activation by two distinct classes of thalidomide analogues that are potent inhibitors of TNF-alpha. J Immunol. 1999;163:380–6.

    PubMed  CAS  Google Scholar 

  20. Haslett PA, Corral LG, Albert M, Kaplan G. Thalidomide costimulates primary human T lymphocytes, preferentially inducing proliferation, cytokine production, and cytotoxic responses in the CD8+ subset. J Exp Med. 1998;187:1885–92.

    Article  PubMed  CAS  Google Scholar 

  21. Anderson G, Gries M, Kurihara N, et al. Thalidomide derivative CC-4047 inhibits osteoclast formation by down-regulation of PU.1. Blood. 2006;107:3098–105.

    Article  PubMed  CAS  Google Scholar 

  22. Koh KR, Janz M, Mapara MY, et al. Immunomodulatory derivative of thalidomide (IMiD CC-4047) induces a shift in lineage commitment by suppressing erythropoiesis and promoting myelopoiesis. Blood. 2005;105:3833–40.

    Article  PubMed  CAS  Google Scholar 

  23. Lentzsch S, LeBlanc R, Podar K, et al. Immunomodulatory analogs of thalidomide inhibit growth of Hs Sultan cells and angiogenesis in vivo. Leukemia. 2003;17:41–4.

    Article  PubMed  CAS  Google Scholar 

  24. D’Amato RJ, Lentzsch S, Anderson KC, Rogers MS. Mechanism of action of thalidomide and 3-aminothalidomide in multiple myeloma. Semin Oncol. 2001;28:597–601.

    Article  PubMed  Google Scholar 

  25. Ferguson G, Jensen-Pergakes K, Wilkey C, et al. Immunomodulatory drug CC-4047 is a cell-type and stimulus-selective transcriptional inhibitor of cyclooxygenase 2. J Clin Immunol. 2007;27:210–20.

    Article  PubMed  CAS  Google Scholar 

  26. • Rajkumar SV, Jacobus S, Callander NS, et al. Lenalidomide plus high-dose dexamethasone versus lenalidomide plus low-dose dexamethasone as initial therapy for newly diagnosed multiple myeloma: an open-label randomised controlled trial. Lancet Oncol. 2010;11:29–37. This trial established lenalidomide with low-dose dexamethasone as the standard for induction.

    Article  PubMed  CAS  Google Scholar 

  27. • Richardson PG, Weller E, Lonial S, et al. Lenalidomide, bortezomib, and dexamethasone combination therapy in patients with newly diagnosed multiple myeloma. Blood. 2010;116:679–86. This trial established the combination of lenalidomide, bortezomib, and dexamethasone.

    Article  PubMed  CAS  Google Scholar 

  28. • Kumar SK, Flinn I, Noga SJ, et al. Bortezomib, dexamethasone, cyclophosphamide and lenalidomide combination for newly diagnosed multiple myeloma: phase 1 results from the multicenter EVOLUTION study. Leukemia. 2010;24:1350–6. This study established the four-drug combination of lenalidomide, bortezomib, cyclophosphamide, and dexamethasone.

    Article  PubMed  CAS  Google Scholar 

  29. • McCarthy PL, Owzar K, Anderson KC, et al. Phase III intergroup study of lenalidomide versus placebo maintenance therapy following single autologous hematopoietic stem cell transplantation (AHSCT) for multiple myeloma: CALGB 100104 [abstract]. ASH Annu Meet Abstr. 2010;116:37. This abstract reports on a CALGB trial of maintenance lenalidomide.

    Google Scholar 

  30. • Attal M, Lauwers VC, Marit G, et al. Maintenance treatment with lenalidomide after transplantation for myeloma: final analysis of the IFM 2005-02 [abstract]. ASH Annu Meet Abstr. 2010;116:310. This abstract reports on the IFM trial of maintenance lenalidomide.

    Google Scholar 

  31. Schey SA, Fields P, Bartlett JB, et al. Phase I study of an immunomodulatory thalidomide analog, CC-4047, in relapsed or refractory multiple myeloma. J Clin Oncol. 2004;22:3269–76.

    Article  PubMed  CAS  Google Scholar 

  32. Streetly MJ, Gyertson K, Daniel Y, Zeldis JB, Kazmi M, Schey SA. Alternate day pomalidomide retains anti-myeloma effect with reduced adverse events and evidence of in vivo immunomodulation. Br J Haematol. 2008;141:41–51.

    Article  PubMed  CAS  Google Scholar 

  33. • Richardson P, Siegel D, Baz R, et al. A phase 1/2 multi-center, randomized, open label dose escalation study to determine the maximum tolerated dose, safety, and efficacy of pomalidomide alone or in combination with low-dose dexamethasone in patients with relapsed and refractory multiple myeloma who have received prior treatment that includes lenalidomide and bortezomib [abstract]. ASH Annu Meet Abstr. 2009;114:301. This abstract reports on a phase I trial of pomalidomide in heavily pretreated patients with refractory MM.

    Google Scholar 

  34. • Lacy MQ, Hayman SR, Gertz MA, et al. Pomalidomide (CC4047) plus low-dose dexamethasone as therapy for relapsed multiple myeloma. J Clin Oncol. 2009;27:5008–14. This article reports the first phase II trial of pomalidomide in relapsed MM.

    Article  PubMed  CAS  Google Scholar 

  35. • Lacy MQ, Hayman SR, Gertz MA, et al. Pomalidomide (CC4047) plus low dose dexamethasone (Pom/dex) is active and well tolerated in lenalidomide refractory multiple myeloma (MM). Leukemia. 2010;24:1934–9. This article reports the first phase II trial of pomalidomide in relapsed lenalidomide-refractory MM.

    Article  PubMed  CAS  Google Scholar 

  36. • Kumar S, Blade J, Crowley J, et al. Natural history of multiple myeloma relapsing after therapy with IMiDs and bortezomib: a multicenter International Myeloma Working Group study [abstract]. ASH Annu Meet Abstr. 2009;114:2878. This abstract reports on prognosis in relapsed MM refractory to bortezomib and IMiD.

    Google Scholar 

  37. • Richardson PG, Siegel D, Baz R, et al. A phase 1/2 multi-center, randomized, open label dose escalation study to determine the maximum tolerated dose, safety, and efficacy of pomalidomide alone or in combination with low-dose dexamethasone in patients with relapsed and refractory multiple myeloma who have received prior treatment that includes lenalidomide and bortezomib [abstract]. ASH Annu Meet Abstr. 2010;116:864. This abstract reports a phase II trial of pomalidomide in heavily pretreated patients with refractory MM.

    Google Scholar 

  38. • Leleu X, Attal M, Moreau P, et al. Phase 2 study of 2 modalities of pomalidomide (CC4047) plus low-dose dexamethasone as therapy for relapsed multiple myeloma. IFM 2009-02 [abstract]. ASH Annu Meet Abstr. 2010;116:859. This abstract reports a phase II trial of pomalidomide in heavily pretreated patients with refractory MM.

    Google Scholar 

  39. • Lacy M, Mandrekar S, Gertz MAA, et al. Pomalidomide plus low-dose dexamethasone in myeloma refractory to both bortezomib and lenalidomide: comparison of two dosing strategies in dual-refractory disease [abstract]. ASH Annu Meet Abstr. 2010;116:863. This abstract reports a phase II trial of pomalidomide in heavily pretreated patients with myeloma that is relapsing and refractory to both bortezomib and lenalidomide.

    Google Scholar 

  40. • Short KD, Rajkumar SV, Buadi F, et al. Increased incidence of extramedullary plasmacytomas in patients with multiple myeloma in the era of novel therapy and effect of pomalidomide on extramedullary disease [abstract]. ASH Annu Meet Abstr. 2010;116:3047. This is the first report of efficacy of pomalidomide in extramedullary disease.

    Google Scholar 

  41. • Geyer H, Viggiano R, Lacy M, et al. Acute lung toxicity related to pomalidomide. Chest. (in press). This is the first report of noninfectious pneumonitis due to pomalidomide.

Download references

Disclosure

Conflicts of interest: M. Lacy: Funds for clinical trials from Celgene.

Author information

Authors and Affiliations

  1. Division of Hematology, Mayo Clinic, 200 First Street SW, Rochester, MN, 55905, USA

    Martha Q. Lacy

Authors
  1. Martha Q. Lacy
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Martha Q. Lacy.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Lacy, M.Q. New Immunomodulatory Drugs in Myeloma. Curr Hematol Malig Rep 6, 120–125 (2011). https://doi.org/10.1007/s11899-011-0077-y

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s11899-011-0077-y

Keywords

Search

Navigation